FDA Issues form 483 to Cipla
Troubles rose again for Cipla Ltd as the US Food and Drug Administration slapped a form 483 with six inspectional observations on the drugmaker's manufacturing facility at Patalganga in Maharashtra. The continued regulatory stress for the company sent its shares down 1.5 percent in early trade on April 5.
Sanofi India said that it has announced an exclusive partnership with Cipla for initial period of five years for distribution and promotion of its central nervous system (CNS) product range in India.
Cipla`s Generic Selexipag Receives Approval in the U.S.
Cipla Limited has announced that a pre-approval inspection was conducted by the United States Food and Drug Administration (USFDA) at the manufacturing facility of Cipla (Jiangsu) Pharmaceutical Co., Ltd. (subsidiary of the Company) located in Qidong, Jiangsu Province, China from 26th February, 2024 to 1st March, 2024. The inspection concluded with zero Form 483 observations.
Cipla partners with CSIR-CDRI to develop formulation for fungal keratitis
Cipla eyes acquisitions, inorganic partnerships in US market
Cipla expects record 24 per cent Ebitda margin in FY24
Samina Hamied of Cipla steps down from her executive role